Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.

Official Title

Long-Term Follow-up Protocol for Subjects Treated With JCAR015

Keywords

Acute Lymphoblastic Leukemia long-term follow-up chimeric antigen receptor (CAR) T cells JCAR015 Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients who have received at least one dose of JCAR015 in a previous treatment protocol.
  • Patients who have provided informed consent for the long-term follow-up study prior to study participation.

You CAN'T join if...

  • None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study.

Locations

  • University of California
    San Francisco, California, 94143, United States
  • City of Hope
    Duarte, California, 91010, United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Juno Therapeutics, Inc.
ID
NCT02813252
Lead Scientist
Study Type
Observational
Last Updated
October 9, 2017